Tymlos (male osteoporosis investigation)
Evidence Grade B — Strong clinical evidence. 373 published studies, 245 human. 23 registered clinical trials.
This entry covers abaloparatide's use in male osteoporosis. The same drug is approved as Tymlos for postmenopausal osteoporosis in women (see the separate abaloparatide entry). Male osteoporosis is an underserved area where fewer treatment options have been formally studied and approved compared to female osteoporosis.
373 published studies: 245 human, 39 animal, 17 in-vitro, 145 reviews
Abaloparatide is approved for postmenopausal osteoporosis (see compound #29). Investigation for male osteoporosis is ongoing. The pivotal ACTIVE trial in women (2,463 patients) demonstrated 86% reduction in vertebral fractures and significant bone density improvements.
Male osteoporosis is an underserved population with fewer approved treatment options. See compound #29 for the approved postmenopausal indication and full clinical data.
Abaloparatide activates the PTH1 receptor with a preference for the receptor conformation that produces bone-building (anabolic) effects over the conformation associated with bone breakdown. This results in net bone formation. The mechanism is the same as described under compound #29 — the investigation is whether the efficacy demonstrated in postmenopausal women translates to men with osteoporosis.
Abaloparatide received FDA approval for male osteoporosis in December 2022, based on a trial of 228 men showing significant bone density improvements. The fracture reduction evidence comes from the larger ACTIVE trial in women (2,463 patients), which demonstrated an 86% reduction in vertebral fractures. The preclinical bone tumour warning limits treatment to a maximum of two years, though post-marketing surveillance has not confirmed this risk in humans. Sequential therapy with an anti-resorptive agent after stopping abaloparatide is recommended to maintain bone density gains. The failed transdermal patch development means injection remains the only delivery option. See the main abaloparatide entry for full clinical details.
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects
Supracondylar Distal Femur Fractures and Abaloparatide
Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis
Sequential Therapies After Osteoanabolic Treatment
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 4
FDA SUPPL 3
FDA SUPPL 7
FDA SUPPL 9
FDA SUPPL 10
EMA Marketing Authorisation
FDA SUPPL 13
FDA SUPPL 15
FDA SUPPL 17
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
